Jeffrey S Wefel

Author PubWeight™ 52.50‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol 2009 9.90
2 A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014 9.19
3 Phase II trial of erlotinib plus concurrent whole-brain radiation therapy for patients with brain metastases from non-small-cell lung cancer. J Clin Oncol 2013 4.72
4 Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol 2013 3.52
5 Randomized double-blind placebo-controlled trial of bevacizumab therapy for radiation necrosis of the central nervous system. Int J Radiat Oncol Biol Phys 2011 2.18
6 Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial. Neuro Oncol 2013 1.88
7 Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol 2013 1.62
8 Neurocognitive function before and after surgery for insular gliomas. J Neurosurg 2011 1.44
9 Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol 2011 1.42
10 The use of the mini-mental state examination to assess cognitive functioning in cancer trials: no ifs, ands, buts, or sensitivity. J Clin Oncol 2003 1.36
11 A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro Oncol 2008 1.23
12 Cancer as a risk factor for dementia: a house built on shifting sand. J Natl Cancer Inst 2005 1.23
13 Default mode network connectivity distinguishes chemotherapy-treated breast cancer survivors from controls. Proc Natl Acad Sci U S A 2013 1.09
14 A pilot study of neurocognitive function in patients with one to three new brain metastases initially treated with stereotactic radiosurgery alone. Neurosurgery 2007 1.05
15 Challenges relating to solid tumour brain metastases in clinical trials, part 2: neurocognitive, neurological, and quality-of-life outcomes. A report from the RANO group. Lancet Oncol 2013 1.03
16 Challenges relating to solid tumour brain metastases in clinical trials, part 1: patient population, response, and progression. A report from the RANO group. Lancet Oncol 2013 1.03
17 Prospective, randomized, controlled trial of parathyroidectomy versus observation in patients with "asymptomatic" primary hyperparathyroidism. Surgery 2009 0.98
18 Early measures of cognitive function predict survival in patients with newly diagnosed glioblastoma. Neuro Oncol 2012 0.98
19 Course of cognitive decline in hematopoietic stem cell transplantation: a within-subjects design. Arch Clin Neuropsychol 2009 0.97
20 Improvement of sleep disturbance and neurocognitive function after parathyroidectomy in patients with primary hyperparathyroidism. Endocr Pract 2007 0.92
21 Congruence of primary brain tumor patient and caregiver symptom report. Cancer 2012 0.88
22 Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Cancer 2013 0.87
23 Cognitive and affective sequelae of primary hyperparathyroidism and early response to parathyroidectomy. J Int Neuropsychol Soc 2009 0.82
24 Relationship between neuropsychological test performance and productivity at 1-year following traumatic brain injury. Clin Neuropsychol 2004 0.81
25 Elevated prefrontal myo-inositol and choline following breast cancer chemotherapy. Brain Imaging Behav 2013 0.80
26 Chemotherapy and cognition: effects, potential mechanisms, and management. Am J Ther 2006 0.80
27 Relationship between cognitive function and prognosis in glioblastoma. CNS Oncol 2013 0.77
28 Neurocognitive Changes Associated With Surgical Resection of Left and Right Temporal Lobe Glioma. Neurosurgery 2015 0.75
29 Reply to v.R. Bhatt et Al and m.C. Chamberlain. J Clin Oncol 2013 0.75